SurgiQuest’s AirSeal System obtains FDA approval for TES

SurgiQuest has obtained 510(k) approval from the US Food and Drug Administration (FDA) for its AirSeal System for transanal endoscopic surgery (TES).

The AirSeal System enables stable insufflation of the rectum and offers continuous smoke evacuation, allowing surgeons to perform TES effectively.

The integrated platform is said to offer valve-free access to the operative cavity during robotic, laparoscopic and other endoscopic surgical procedures.

Florida Hospital colorectal fellowship program director Dr Matthew Albert said: "The AirSeal System has had a significant impact on our ability to perform both TAMIS and TaTME procedures.

"From the first time I used it clinically, I knew this technology would elevate our surgical capabilities, improve patient outcomes, and help reduce procedure time and costs."

According to SurgiQuest, the category of transanal endoscopic surgery comprises transanal minimally invasive surgery (TAMIS) and transanal total mesorectal excision (TaTME), a surgical technique that demonstrated enhanced patient outcomes in colorectal cancer procedures.

SurgiQuest develops, manufactures and markets new access technologies for minimally invasive surgery.